The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Novartis Ireland Limited .

Filed returns
32
match these filters
Matching filed returns per period 0 2 5 7 10 Sep–Dec 2015: 2 filed returns Sep–Dec 2016: 1 filed returns May–Aug 2017: 1 filed returns May–Aug 2021: 1 filed returns Jan–Apr 2023: 1 filed returns May–Aug 2023: 1 filed returns Sep–Dec 2023: 2 filed returns Jan–Apr 2024: 2 filed returns May–Aug 2024: 3 filed returns Sep–Dec 2024: 2 filed returns Jan–Apr 2025: 1 filed returns May–Aug 2025: 2 filed returns Sep–Dec 2025: 6 filed returns Jan–Apr 2026: 4 filed returns May–Aug 2026: 3 filed returns 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
May–Aug 2026 Novartis Ireland Limited Health National Cardiovascular Health Strategy (Public policy or programme) 5 On lobbying.ie
May–Aug 2026 Novartis Ireland Limited Health Health System Readiness for Advanced Cancer Therapy (Public policy or programme) 1 On lobbying.ie
May–Aug 2026 Novartis Ireland Limited Health Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) 27 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health Attended an event for World Cancer Day (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) 26 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health Roundtable policy meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) 5 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health Implementation of the decision to include SMA in newborn screening (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Invitation to a meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) 14 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health American Chamber of Commerce Event (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health AI4Ireland meeting with Oireachtas members (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health World Urticaria Day event (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Invited to the Joint Oireachtas All Party Committee on Orphan Drugs (3/12/25) (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Advocate for Life Science Strategy (Public policy or programme) 7 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Rare Disease Ireland invite to Leinster House (Public policy or programme) 5 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Timely inclusion of SMA in heel prick test (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2025 Novartis Ireland Limited Health Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2024 Novartis Ireland Limited Health Life Sciences strategy for Ireland (Public policy or programme) 9 On lobbying.ie
Sep–Dec 2024 Novartis Ireland Limited Health Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) 7 On lobbying.ie
May–Aug 2024 Novartis Ireland Limited Health To fund an Office of Life Sciences or Life Science Strategy (Matters involving public funds) 1 On lobbying.ie
May–Aug 2024 Novartis Ireland Limited Health Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) 25 On lobbying.ie
May–Aug 2024 Novartis Ireland Limited Health Access in Heart Failure (HF) & healthcare system readiness for new medicine platforms like radioligand therapies. Clinical trial attractiveness (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2024 Novartis Ireland Limited Health Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) 6 On lobbying.ie
Jan–Apr 2024 Novartis Ireland Limited Health Ensure that the healthcare system is ready for new novel treatments like radioligand therapies. Also employing guideline-directed therapy for heart failure patients. (Matters involving public funds) 2 On lobbying.ie
Sep–Dec 2023 Novartis Ireland Limited Health Budget for innovative new medicines in 2024 (Matters involving public funds) 5 On lobbying.ie
Sep–Dec 2023 Novartis Ireland Limited Health Expansion of newborn screening in Ireland (Matters involving public funds) 3 On lobbying.ie
May–Aug 2023 Novartis Ireland Limited Health Ensuring the spinal muscular atrophy (SMA) is added to the heel prick test in a timely manner (Matters involving public funds) 11 On lobbying.ie
Jan–Apr 2023 Novartis Ireland Limited Health Expension of the newborn screening program - adding more diseases to the heel prick test (Matters involving public funds) 3 On lobbying.ie
May–Aug 2021 Novartis Ireland Limited Health New born screening, timely access to new medicines in Ireland (Public policy or programme) 1 On lobbying.ie
May–Aug 2017 Novartis Ireland Limited Health Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) 23 On lobbying.ie
Sep–Dec 2016 Novartis Ireland Limited Health Making Heart Failure a public policy priority (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2015 Novartis Ireland Limited Health Highlighting the societal cost of multiple scelerosis (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2015 Novartis Ireland Limited Health Making heart failure a national priority (Public policy or programme) 19 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 32 100.0%